COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00331422
Recruitment Status : Terminated (Study was terminated due to lack of available funding.)
First Posted : May 31, 2006
Results First Posted : February 8, 2010
Last Update Posted : December 28, 2017
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving chemotherapy drugs before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin before surgery works in treating patients with advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.

Condition or disease Intervention/treatment Phase
Fallopian Tube Cancer Ovarian Cancer Peritoneal Cavity Cancer Drug: carboplatin Drug: paclitaxel Procedure: cytoreductive surgery Phase 2

Detailed Description:



  • Determine whether at least 50% of patients with advanced ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer are able to achieve optimal cytoreduction (to < 1 centimeter of remaining disease) after neoadjuvant chemotherapy comprising paclitaxel and carboplatin.


  • Determine the frequency and severity of toxicity associated with this regimen in patients who are high-risk surgical candidates or in patients unlikely to achieve optimal surgical cytoreduction.
  • Determine if extreme drug resistance assay profiles change after neoadjuvant chemotherapy.
  • Determine how thrombospondin-1 (TSP-1), tumor protein 53 (p53), and tumor vessel density change after administration of neoadjuvant chemotherapy.
  • Assess the quality of life of patients receiving neoadjuvant chemotherapy.
  • Obtain estimates of tumor response after administration of neoadjuvant chemotherapy.
  • Determine whether serum cancer antigen 125 (CA-125) at the time of cytoreduction is associated with the ability to optimally reduce the patients.

OUTLINE: This is an open-label study.

Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Within 4-6 weeks after the fourth course of chemotherapy, patients undergo interval cytoreductive surgery.

Patients who are unable to undergo surgery receive 2 additional courses of chemotherapy and are re-evaluated for surgery after the sixth course of chemotherapy.

Within 4 weeks after surgery, patients receive 2 additional courses of chemotherapy.

Quality of life is assessed periodically.

Tumor samples are obtained via laparoscopic or percutaneous biopsy prior to beginning chemotherapy and during interval cytoreduction. Tissue is examined by immunohistochemistry staining for p53, TSP-1, microvessel density (CD31), angiogenesis, membrane protein BCL-2, and multidrug resistant gene 1 (MDR-1). Gene array analysis and extreme drug resistant assays are also performed.

After completion of study treatment, patients are followed every 3 months for 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced
Study Start Date : October 2005
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2009

Arm Intervention/treatment
Experimental: Patients Who Received Treatment
All patients receiving treatment with Paclitaxel and Carboplatin followed by surgery to remove cancerous tissue.
Drug: carboplatin
Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
Other Name: Paraplatin

Drug: paclitaxel
Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
Other Name: Taxol

Procedure: cytoreductive surgery
Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
Other Names:
  • surgery
  • debulking

Primary Outcome Measures :
  1. Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy [ Time Frame: Week 18 (After 4 cycles of chemotherapy) ]
    These patients had their tumor(s) removed by surgery after receiving 4 cycles of chemotherapy to determine their response.

Secondary Outcome Measures :
  1. Patients' Overall Tumor Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Week 16 (4 weeks after 4th course) ]
    Best response recorded from start of treatment until after 4th cycle of treatment. Defined by the sum of Complete Responses (CR), Partial Responses (PR), and Stable Disease (SD) in patients neoadjuvant chemotherapy. CR=disappearance of all lesions, PR=>or=30% decrease in sumof all target lesins, Progressive Disease (PD) =>or =20% increase in sum of all target or any new lesions, SD=not CR, PR or PD.

  2. Clinical Response Based on Serum Cancer Antigen 125 (CA-125) Concentration [ Time Frame: From Baseline to up to 12 weeks (4 courses of therapy) ]
    Ca-125 serum results compared from baseline to after patient's last treatment. This is a tumor biomarker. A decrease in results indicates a clinical response.

  3. Change in Drug Resistance After Neoadjuvant Chemotherapy [ Time Frame: Day 1 to Time to Surgery (Approximately Week 18) ]
    As measured by extreme drug resistance assay - Unable to report due to tissue samples being incomplete or unsatisfactory to do laboratory testing.

  4. Change in Thrombospondin-1 (TSP-1), p53, and Tumor Vessel Density [ Time Frame: Week 18 (At surgery) ]
    Unable to report due to incomplete (nonviable) or unsatisfactory tissue samples.

  5. Quality of Life Score of Patients Receiving Neoadjuvant Chemotherapy [ Time Frame: Day 1, Week 12 (after 4th course) , Week 16 (4 weeks after last treatment) ]

    Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Questionnaire was used to assess the impact of treatment- and disease-related factors on the quality of life of patients with ovarian cancers undergoing chemotherapy. It is a 5 point scale (from worse to best: 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much responses). Physical well-being, social/family well-being, functional well-being, emotional well-being and additional concerns questions are asked.

    Unable to evaluate; patients did not consistently complete the questionnaires.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube carcinoma for which no previous treatment has been given.

Patients with the following histological epithelial cell types are eligible:

  • Serous adenocarcinoma
  • Mucinous adenocarcinoma
  • Clear cell adenocarcinoma
  • Transitional cell
  • Adenocarcinoma not otherwise specified
  • Endometrioid adenocarcinoma
  • Undifferentiated carcinoma
  • Mixed epithelial carcinoma
  • Malignant Brenner's tumor

    • Measurable or non-measurable disease as defined by Solid Tumor Response Criteria (RECIST) within 4 weeks of study entry
    • High-risk surgical candidate
    • Gynecologic Oncology Group (GOG) performance status 0-3
    • Absolute neutrophil count ≥ 1,500/mm^3
    • Platelet count ≥ 100,000/mm^3
    • Creatinine ≤ 1.5 mg/dL
    • Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)
    • Bilirubin ≤ 1.5 times ULN
    • Serum glutamic oxaloacetic transaminase (SGOT) ≤ 3 times ULN
    • Life expectancy ≥ 12 weeks

Exclusion Criteria:

  • Pregnant or nursing
  • Positive pregnancy test -(Fertile patients must use effective nonhormonal contraception during and for 3 months after completion of study treatment.)
  • History of another neoplasm except for non-metastatic, non-melanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery > 5 years prior to registration.
  • Septicemia, severe infection, acute hepatitis, or severe gastrointestinal bleeding, defined as requiring blood transfusion or hospitalization at registration
  • Unstable angina will not be eligible. Patients with evidence of abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible if their disease has been stable for the past six months.
  • History of severe hypersensitivity or allergic reaction to study drugs, drugs formulated in Cremophor EL^®, other platinol compounds, or mannitol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00331422

Layout table for location information
United States, Minnesota
University of Minnesota Cancer Center
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Layout table for investigator information
Study Chair: Melissa A. Geller, MD Masonic Cancer Center, University of Minnesota
Layout table for additonal information
Responsible Party: Masonic Cancer Center, University of Minnesota Identifier: NCT00331422    
Other Study ID Numbers: 2004LS070
UMN-0409M64006 ( Other Identifier: Institutional Review Board, University of Minnesota )
UMN- WCC-40 ( Other Identifier: Women's Cancer Center, University of Minnesota )
First Posted: May 31, 2006    Key Record Dates
Results First Posted: February 8, 2010
Last Update Posted: December 28, 2017
Last Verified: December 2017
Keywords provided by Masonic Cancer Center, University of Minnesota:
ovarian clear cell cystadenocarcinoma
ovarian endometrioid adenocarcinoma
ovarian mixed epithelial carcinoma
ovarian mucinous cystadenocarcinoma
ovarian serous cystadenocarcinoma
ovarian undifferentiated adenocarcinoma
stage III ovarian epithelial cancer
stage IV ovarian epithelial cancer
peritoneal cavity cancer
fallopian tube cancer
Brenner tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Neoplasms by Site
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Fallopian Tube Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action